Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Regenxbio stock

Learn how to easily invest in Regenxbio stock.

Regenxbio Inc is a biotechnology business based in the US. Regenxbio shares (RGNX) are listed on the NASDAQ and all prices are listed in US Dollars. Regenxbio employs 372 staff and has a trailing 12-month revenue of around $484.3 million.

How to buy shares in Regenxbio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RGNX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Regenxbio stock price (NASDAQ: RGNX)

Use our graph to track the performance of RGNX stocks over time.

Regenxbio shares at a glance

Information last updated 2022-09-18.
Latest market close$22.86
52-week range$18.69 - $44.44
50-day moving average $30.96
200-day moving average $28.20
Wall St. target price$51.50
PE ratio 12.3128
Dividend yield $0 (0%)
Earnings per share (TTM) $2.11

Buy Regenxbio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Regenxbio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Regenxbio price performance over time

Historical closes compared with the close of $22.86 from 2022-09-23

1 week (2022-09-16) -12.01%
1 month (2022-08-25) -32.51%
3 months (2022-06-24) -13.74%
6 months (2022-03-24) -28.47%
1 year (2021-09-24) -45.98%
2 years (2020-09-25) -17.92%
3 years (2019-09-25) 34.86
5 years (2017-09-25) 30.95

Is Regenxbio stock undervalued or overvalued?

Valuing Regenxbio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regenxbio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Regenxbio's P/E ratio

Regenxbio's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Regenxbio shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Regenxbio's PEG ratio

Regenxbio's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.26. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regenxbio's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Regenxbio's EBITDA

Regenxbio's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $132.9 million.

The EBITDA is a measure of a Regenxbio's overall financial performance and is widely used to measure a its profitability.

Regenxbio financials

Revenue TTM $484.3 million
Operating margin TTM 25.23%
Gross profit TTM $237.1 million
Return on assets TTM 8.53%
Return on equity TTM 15.95%
Profit margin 18.73%
Book value $14.61
Market capitalisation $1.1 billion

TTM: trailing 12 months

Regenxbio share dividends

We're not expecting Regenxbio to pay a dividend over the next 12 months.

Regenxbio share price volatility

Over the last 12 months, Regenxbio's shares have ranged in value from as little as $18.69 up to $44.44. A popular way to gauge a stock's volatility is its "beta".

RGNX.US volatility(beta: 1.09)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regenxbio's is 1.0927. This would suggest that Regenxbio's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Regenxbio overview

REGENXBIO Inc. , a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies.

Frequently asked questions

What percentage of Regenxbio is owned by insiders or institutions?
Currently 12.097% of Regenxbio shares are held by insiders and 91.514% by institutions.
How many people work for Regenxbio?
Latest data suggests 372 work at Regenxbio.
When does the fiscal year end for Regenxbio?
Regenxbio's fiscal year ends in December.
Where is Regenxbio based?
Regenxbio's address is: 9804 Medical Center Drive, Rockville, MD, United States, 20850
What is Regenxbio's ISIN number?
Regenxbio's international securities identification number is: US75901B1070
What is Regenxbio's CUSIP number?
Regenxbio's Committee on Uniform Securities Identification Procedures number is: 75901B107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site